<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03541928</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00017515</org_study_id>
    <nct_id>NCT03541928</nct_id>
  </id_info>
  <brief_title>Phase II High Risk Prostate Cancer Trial Using Gene &amp; Androgen Deprivation Therapies, Radiotherapy, &amp; Surgery</brief_title>
  <official_title>Phase II Study Evaluating HSV-tk + Valacyclovir Gene Therapy in Combination With Androgen Deprivation Therapy, Brachytherapy, External Beam Radiotherapy, and Prostatectomy for High-Risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Methodist Hospital System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Methodist Hospital System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective phase II study to assess the efficacy and toxicity of HSV-tk+
      valacyclovir gene therapy in combination with androgen deprivation therapy, brachytherapy,
      external beam radiotherapy, and prostatectomy in previously untreated high-risk prostate
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase II study plans to assess efficacy and toxicity of HSV-tk+ valacyclovir gene
      therapy in combination with androgen deprivation therapy, brachytherapy, external beam
      radiotherapy, and prostatectomy in previously untreated high-risk prostate cancer patients.

      Clinical response as evaluated by changes in serum PSA level and digital rectal examination
      as well as by histological alterations on re-biopsy and prostatectomy such as the presence of
      apoptosis, necrosis, tumor proliferation and immunologic response, will be assessed following
      HSV-tk + valacyclovir treatment. Blood samples will be taken for systemic immunological
      response, blood counts and liver functions tests. Toxicity will be graded by the Common
      Terminology Criteria for Adverse Events (CTCAE) and Radiation Therapy Oncology Group (RTOG)
      neuro-toxicity scores (See Appendices). Additionally, patients will be followed closely to
      assess nadir PSA, freedom from PSA-progression, and freedom from local and distant
      progression and overall survival.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2, 2018</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical control rate</measure>
    <time_frame>5-year biochemical disease free survival rate</time_frame>
    <description>measured by PSA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>5-year overall survival rate</time_frame>
    <description>Measured at the end of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic complete response rate</measure>
    <time_frame>After prostatectomy</time_frame>
    <description>Measured by pathologic result of prostatectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety based on questionnaire and clinical adverse event monitoring</measure>
    <time_frame>5-year post treatment</time_frame>
    <description>Measured by the Sexual Health Inventory for Men (SHIM), the International Prostate Symptoms Score (IPSS), and the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>High-risk Prostate Cancer</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Gene Therapy, ADT, RT, and Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The investigational gene therapy, ADV/HSV-tk, will be administered by injection into the prostate at 5 x 10[11] virus particles (1.25 x 10[11] virus particles per tumor quadrant in 4 quadrants) on day 0 and day 30.
The recommended dose of Valacyclovir for this trial is 2 g orally t.i.d. for 14 days (day 1 to day 15 and days 31 to 45).
The recommended dose for Bicalutamide therapy in combination with an LHRH analogue is one 50 mg tablet once daily (morning or evening).
Leuprolide acetate 7.5mg depot injection will be injected monthly for a total of 2 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSV-Tk</intervention_name>
    <description>Injection of the HSV-tk gene therapy product in four quadrants of prostate to enhance the immune system via &quot;bystander effect&quot; in which cytotoxicity is conferred to non-transduced neighboring cells. In vivo bystander effects are likely due to a combination of host immunological responses and to gap junction-mediated transport of phosphorylated prodrug metabolites to surrounding cells.</description>
    <arm_group_label>Gene Therapy, ADT, RT, and Surgery</arm_group_label>
    <other_name>Gene therapy</other_name>
    <other_name>AdV-tk gene therapy</other_name>
    <other_name>Herpes simplex virus thymidine kinase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valacyclovir</intervention_name>
    <description>The recommended dose for this trial is 2 g orally t.i.d. for 14 days (day 1 to day 15 and days 31 to 45). This dose has been calculated to give a similar AUC as 10 mg/kg of intravenous acyclovir administered every 8 hours. This is the same dose regimen used in a previous phase I clinical trial of ADV/HSV-tk plus acyclovir and topotecan in patients with recurrent ovarian cancer.</description>
    <arm_group_label>Gene Therapy, ADT, RT, and Surgery</arm_group_label>
    <other_name>Valtrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bicalutamide</intervention_name>
    <description>The recommended dose for Bicalutamide therapy in combination with an LHRH analogue is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that Bicalutamide be taken at the same time each day.
The use of an oral antiandrogen with medical castration for the treatment of prostate cancer is referred to as combined androgen blockade (CAB). Compared with LHRH-agonist monotherapy, CAB with bicalutamide did not reduce overall QoL but provided an early improvement in QoL related to lower urinary tract symptoms and pain.</description>
    <arm_group_label>Gene Therapy, ADT, RT, and Surgery</arm_group_label>
    <other_name>Casodex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide Acetate</intervention_name>
    <description>Leuprolide acetate 7.5 mg depot injection will be injected monthly for a total of 2 months.</description>
    <arm_group_label>Gene Therapy, ADT, RT, and Surgery</arm_group_label>
    <other_name>Lupron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Brachytherapy, External beam radiotherapy</intervention_name>
    <description>On day 60, patient will undergo high dose rate (HDR) Brachytherapy. The patient will have 8-14 needle catheters inserted under ultrasound guidance. CT simulation and radiation treatment planning will be performed. The needle catheters will be connected to an HDR afterloader containing an Iridium 192 source. A single dose of 1250cGy will be delivered.</description>
    <arm_group_label>Gene Therapy, ADT, RT, and Surgery</arm_group_label>
    <other_name>HDR</other_name>
    <other_name>EBRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical prostatectomy</intervention_name>
    <description>approximately 2-3 weeks after radiotherapy completion, patient will undergo radical retropubic prostatectomy. Use of laparoscopy or robotic assistance will be at the urologist's discretion. Lymph node dissection will be performed.</description>
    <arm_group_label>Gene Therapy, ADT, RT, and Surgery</arm_group_label>
    <other_name>Prostatectomy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients must have biopsy proven adenocarcinoma of the prostate

          -  Patients in should have at least one or more of the following characteristics PSA&gt;20,
             Gleason score 8-10, Primary Gleason pattern 5, &gt;4 cores with Gleason 8-10, and
             Clinical stage T3a-T4.

          -  No prior surgical, hormonal, or radiotherapy prostate treatment.

          -  ECOG performance status 0-1

          -  No evidence of metastatic disease or other malignancy (except squamous or basal cell
             skin cancers.

          -  Patients must have PSA within 3 months of entry.

          -  Signed informed consent to participate in the study must be obtained from patients
             after they have been fully informed of the nature and potential risks of the study by
             the investigator (or his/her designee) with the aid of written information.

          -  Willing to provide biopsies as required by the study.

          -  Patients must have adequate baseline organ function as assessed by the following
             laboratory values before initiating the protocol:

          -  serum creatinine &lt; 1.5 mg%

          -  T. bilirubin &lt; 2.5 mg%, ALT and AST &lt; 2x normal

          -  Pts &gt; 100,000/mm3 , ANC&gt; 1500 mm , Hgb&gt; 10gm%

          -  Normal partial thromboplastin time (PTT) and Pro-Thrombin Time (PT)

        Exclusion Criteria:

          -  Prior treatment with immunomodulatory therapy, immunotherapy, and/or gene vector
             therapy in the past 3 months.

          -  Any cytotoxic chemotherapy, RT, or immunotherapy or any investigational drug within 3
             weeks of study treatment start.

          -  Evidence of metastatic disease

          -  Prostate volume &gt;50cc

          -  Prior prostate surgery (hyperthermia, cryotherapy, etc.)

          -  Prior pelvic radiotherapy

          -  Prior androgen ablation hormonal therapy (except finasteride if discontinued &gt; 3 mo.
             prior to enrollment)

          -  Patients on corticosteroids or any immunosuppressive drugs.

          -  History of liver disease, such as cirrhosis or active/chronic hepatitis B or C.

          -  History of or current alcohol misuse/abuse within the past 12 months.

          -  Known or suspected allergy or hypersensitivity to any component of the proposed
             regimen (gene vector/Valacyclovir).

          -  Inability to swallow food or any condition of the upper gastrointestinal tract that
             precludes administration of oral medications (Valacyclovir).

          -  No active malignancy except for non-melanoma skin cancer or in situ cervical cancer or
             treated cancer from which the patient has been continuously disease free for more than
             5 years.

          -  Presence of active or suspected acute or chronic uncontrolled infection or history of
             immunocompromise, including a positive HIV test result.

          -  Patients &lt; 18 years of age

          -  Unwilling or unable to comply with the study protocol.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E. Brian Butler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Methodist Hospital System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emily Hsiao, Ph.D.</last_name>
    <phone>713-383-5115</phone>
    <email>khsiao@houstonmethodist.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine O'Reilly</last_name>
    <phone>713-394-1107</phone>
    <email>coreilly@houstonmethodist.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward B Butler</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010 Dec 15;127(12):2893-917. doi: 10.1002/ijc.25516.</citation>
    <PMID>21351269</PMID>
  </reference>
  <reference>
    <citation>Zagars GK, Pollack A, Kavadi VS, von Eschenbach AC. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1995 May 15;32(2):293-306.</citation>
    <PMID>7538498</PMID>
  </reference>
  <reference>
    <citation>Al-Mamgani A, van Putten WL, van der Wielen GJ, Levendag PC, Incrocci L. Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):1004-12. doi: 10.1016/j.ijrobp.2009.12.039. Epub 2010 Apr 24.</citation>
    <PMID>20421153</PMID>
  </reference>
  <reference>
    <citation>Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1520-9.</citation>
    <PMID>15050332</PMID>
  </reference>
  <reference>
    <citation>Teh BS, Aguilar-Cordova E, Vlachaki MT, Aguilar L, Mai WY, Caillouet J, Davis M, Miles B, Kadmon D, Ayala G, Lu HH, Chiu JK, Carpenter LS, Woo SY, Grant WH 3rd, Wheeler T, Thompson TC, Butler EB. Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancer. Oncologist. 2002;7(5):458-66.</citation>
    <PMID>12401909</PMID>
  </reference>
  <reference>
    <citation>Yossepowitch O, Eggener SE, Bianco FJ Jr, Carver BS, Serio A, Scardino PT, Eastham JA. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol. 2007 Aug;178(2):493-9; discussion 499. Epub 2007 Jun 11.</citation>
    <PMID>17561152</PMID>
  </reference>
  <reference>
    <citation>Freytag SO, Stricker H, Pegg J, Paielli D, Pradhan DG, Peabody J, DePeralta-Venturina M, Xia X, Brown S, Lu M, Kim JH. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res. 2003 Nov 1;63(21):7497-506.</citation>
    <PMID>14612551</PMID>
  </reference>
  <reference>
    <citation>Freytag SO, Movsas B, Aref I, Stricker H, Peabody J, Pegg J, Zhang Y, Barton KN, Brown SL, Lu M, Savera A, Kim JH. Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol Ther. 2007 May;15(5):1016-23. Epub 2007 Mar 20.</citation>
    <PMID>17375076</PMID>
  </reference>
  <reference>
    <citation>Crook J, Ludgate C, Malone S, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G. Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):327-33. doi: 10.1016/j.ijrobp.2008.04.075. Epub 2008 Aug 15.</citation>
    <PMID>18707821</PMID>
  </reference>
  <reference>
    <citation>Golden EB, Pellicciotta I, Demaria S, Barcellos-Hoff MH, Formenti SC. The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol. 2012 Aug 7;2:88. doi: 10.3389/fonc.2012.00088. eCollection 2012.</citation>
    <PMID>22891162</PMID>
  </reference>
  <reference>
    <citation>Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, Tsang KY, Yokokawa J, Hodge JW, MÃ©nard C, Camphausen K, Coleman CN, Sullivan F, Steinberg SM, Schlom J, Dahut W. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res. 2005 May 1;11(9):3353-62. Erratum in: Clin Cancer Res. 2006 Jan 1;12(1):322.</citation>
    <PMID>15867235</PMID>
  </reference>
  <reference>
    <citation>Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51-72. doi: 10.1146/annurev-immunol-032712-100008. Epub 2012 Nov 12. Review.</citation>
    <PMID>23157435</PMID>
  </reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>May 10, 2018</study_first_submitted>
  <study_first_submitted_qc>May 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2018</study_first_posted>
  <last_update_submitted>October 24, 2018</last_update_submitted>
  <last_update_submitted_qc>October 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Methodist Hospital System</investigator_affiliation>
    <investigator_full_name>E. Brian Butler</investigator_full_name>
    <investigator_title>Chair of Radiation Oncology Department, Houston Methodist Hospital</investigator_title>
  </responsible_party>
  <keyword>gene therapy</keyword>
  <keyword>untreated prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

